BiotechTube

Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867)

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Burns

Conditions

Burns, Bacterial Infections

Trial Timeline

Nov 1, 2002 → Nov 1, 2003

NCT ID
NCT00668044

About Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867)

Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867) is a phase 3 stage product being developed by Bayer for Burns. The current trial status is completed. This product is registered under clinical trial identifier NCT00668044. Target conditions include Burns, Bacterial Infections.

What happened to similar drugs?

3 of 5 similar drugs in Burns were approved

Approved (3) Terminated (3) Active (2)
✅Ceftolozane/tazobactamMerckApproved
✅Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsViatrisApproved
✅Pathogen-Reduced Plasma + Crystalloid SolutionsCerusApproved
🔄NexoBrid + Gel VehicleMediWoundPhase 3
🔄NexoBridMediWoundPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00668044Phase 3Completed

Competing Products

12 competing products in Burns

See all competitors
ProductCompanyStageHype Score
R-Pdf/Gbb 0.01% gelJohnson & JohnsonPhase 2
31
Ceftolozane/tazobactamMerckApproved
35
linezolidPfizerPhase 1
29
Somatropin + 0.09% Saline SolutionPfizerPhase 2/3
38
cP12United TherapeuticsPhase 2
39
cNP8United TherapeuticsPhase 1
26
Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsViatrisApproved
32
Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL ThrombinBaxterPhase 1/2
29
I-020502BaxterPhase 2
32
Pathogen-Reduced Plasma + Crystalloid SolutionsCerusApproved
25
NexoBrid + Gel VehicleMediWoundPhase 3
30
NexoBridMediWoundPhase 3
30